Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roskos, S. E.
Right arrow Articles by Weiss, B. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roskos, S. E.
Right arrow Articles by Weiss, B. D.
American Journal of Health-System Pharmacy, Vol. 65, Issue 1, 65-68
Copyright © 2008. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00


Notes

Readability of consumer medication information for intranasal corticosteroid inhalers

Steven E. Roskos, Lorraine S. Wallace and Barry D. Weiss

STEVEN E. ROSKOS, M.D., is Assistant Professor, Department of Family Medicine, Michigan State University, East Lansing; when this article was written, he was Assistant Professor, Department of Family Medicine, University of Tennessee Graduate School of Medicine (UTGSM), Knoxville. LORRAINE S. WALLACE, PH.D., is Associate Professor, Department of Family Medicine, UTGSM. BARRY D. WEISS, M.D., is Professor, Department of Family and Community Medicine, University of Arizona College of Medicine, Tucson.

Address correspondence to Dr. Wallace at the Department of Family Medicine, University of Tennessee Graduate School of Medicine, 1924 Alcoa Highway, U-67, Knoxville, TN 37920 (lwallace{at}mc.utmck.edu).


Purpose. The readability of consumer medication information (CMI) inserts accompanying intranasal corticosteroid (INCS) inhalers currently prescribed in the United States was studied.

Methods. INCS inhalers were identified (n = 7) using Epocrates Rx Pro and English- language CMI was obtained from each inhaler’s manufacturer. The CMI was evaluated for reading grade level (using Fry’s readability formula) and font size, dimensions (length and width), illustrations (diagrams and figures), and directions for use.

Results. The mean ± S.D. reading grade level of the CMI was 6.9 ± 0.7 (range, 6–8). The mean ± S.D. font size was 9.0 ± 2.2 (range, 6–12). The mean ± S.D. CMI page length and width were 31.3 ± 22.5 cm and 14.0 ± 12.9 cm, respectively. A device-overview figure was included in three of the seven educational samples. The mean size of illustrations was 7.9 cm2 (range, 2.9–25.9 cm2), with a mean ± S.D. of 7.6 ± 3.2 (range, 3–11) figures per CMI insert. Directions followed a logical, step-by-step chronological sequence in every CMI insert.

Conclusion. Most CMI for INCS inhalers is written at a reading level slightly higher than recommended, printed in a font size smaller than recommended, and illustrated inadequately for successful patient education.

Index terms: Drug administration routes; Inhalers; Patient information; Readability; Steroids, cortico-

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Health-System Pharmacists.